Related Experiment Video
Updated: Jul 14, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism
Dalila Andrade Pereira1, Danillo Andrade Pereira1, Pamela da Silva Pereira2
1Laboratory of Pharmacology, São Francisco University Medical School, Bragança Paulista, São Paulo, Brazil.
Insights
Hydroxyurea does not effectively treat priapism in sickle cell disease (SCD) mice. This is likely due to excess hemoglobin and reactive oxygen species interfering with nitric oxide signaling in SCD. Alternative therapies are needed.
Area of Science:
- Pharmacology
- Urology
- Genetics
Background:
- Sickle cell disease (SCD) is linked to priapism.
- The impact of hydroxyurea on the nitric oxide (NO)-cGMP pathway in SCD-associated priapism is not well understood.
Purpose of the Study:
- To investigate hydroxyurea's effect on corpus cavernosum smooth muscle relaxation in SCD and endothelial NO synthase gene-deficient (eNOS-/-) mice models of priapism.
Main Methods:
- Male wild-type, SCD transgenic, and eNOS-/- mice were treated with hydroxyurea or vehicle.
- Concentration-response curves for acetylcholine, sodium nitroprusside, and electrical field stimulation were generated using corpus cavernosum strips.
Main Results:
- SCD mice showed amplified relaxation responses to acetylcholine, sodium nitroprusside, and electrical field stimulation.
- eNOS-/- mice exhibited heightened relaxation responses to sodium nitroprusside and electrical field stimulation.
- Hydroxyurea treatment did not alter these relaxation responses in either SCD or eNOS-/- mice.
Conclusions:
- Hydroxyurea is ineffective for treating priapism in sickle cell disease.
- Excess hemoglobin and reactive oxygen species in SCD may interfere with NO signaling, hindering hydroxyurea's efficacy.
- Alternative therapeutic strategies are urgently needed for priapism in SCD.
Abstract:
Sickle cell disease (SCD) is a genetic disorder that has been associated with priapism. The role of hydroxyurea, a common SCD therapy, in influencing the nitric oxide (NO)-cGMP pathway and its effect on priapism is unclear. To investigate the effect of hydroxyurea treatment on smooth muscle relaxation of corpus cavernosum induced by stimulation of the NO-cGMP pathway in SCD transgenic mice and endothelial NO synthase gene-deficient (eNOS-/-) mice, which are used as model of priapism associated with the low bioavailability of endothelial NO. Four-month-old wild-type (WT, C57BL/6), SCD transgenic, and eNOS-/- male mice were treated with hydroxyurea (100 mg/Kg/day) or its vehicle (saline) daily for three weeks via intraperitoneal injections. Concentration-response curves for acetylcholine (ACh), sodium nitroprusside (SNP), and electrical field stimulation (EFS) were generated using strips of mice corpus cavernosum. The SCD mice demonstrated an amplified CC relaxation response triggered by ACh, EFS, and SNP. The corpus cavernosum relaxation responses to SNP and EFS were found to be heightened in the eNOS-/- group. However, the hydroxyurea treatment did not alter these escalated relaxation responses to ACh, EFS, and SNP in the corpus cavernosum of the SCD group, nor the relaxation responses to EFS and SNP in the eNOS-/- group. In conclusion, hydroxyurea is not effective in treating priapism associated with SCD. It is likely that excess plasma hemoglobin and reactive oxygen species, which are reported in SCD, are reacting with NO before it binds to GCs in the smooth muscle of the corpus cavernosum, thus preventing the restoration of baseline NO/cGMP levels. Furthermore, the downregulation of eNOS in the penis may impair the pharmacological action of hydroxyurea at the endothelial level in SCD mice. This study emphasize the urgency for exploring alternative therapeutic avenues for priapism in SCD that are not hindered by high plasma hemoglobin and ROS levels.
Related Concept Videos
Nitric Oxide Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators

